Skip to main content
SpringerLink
Log in

Behandlung depressiver Störungen

  • Chapter
  • First Online:
Polypharmazie in der Behandlung psychischer Erkrankungen

Zusammenfassung

Viele der derzeit gültigen Therapiestandards empfehlen in der Behandlung psychischer Erkrankungen nachdrücklich eine Monotherapie. In der klinischen Praxis werden jedoch in der Depressionsbehandlung mehr oder weniger häufig Kombinations- oder Augmentationsbehandlungen durchgeführt. Eine internationale, konsentierte Definition existiert bislang nicht, sodass nachfolgend eine Kombination als die gleichzeitige Verordnung von zwei oder mehreren Antidepressiva von einer Augmentation als der simultanen Verordnung eines Antidepressivums mit einem oder mehreren (Psycho-)Pharmaka einer anderen Kategorie unterschieden wird. In diesem Beitrag sollen die wesentlichen Kombinations- und Augmentationsstrategien bei depressiven Erkrankungen dargestellt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Adli M, Hollinde DL, Stamm T et al. (2007) Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta-50T/C single nucleotide polymorphism. Biol Psychiatry 62: 1295–1302

    Article  CAS  PubMed  Google Scholar 

  • Adson DE, Kushner MG, Eiben KM, Schulz SC (2004) Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety 19: 121–126

    Article  CAS  PubMed  Google Scholar 

  • Agid O, Lerer B (2003) Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int J Neuropsychopharmacol 6: 41–49

    Article  CAS  PubMed  Google Scholar 

  • Alpert JE, Papakostas G, Mischoulon D et al. (2004) S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 24: 661–664

    Article  CAS  PubMed  Google Scholar 

  • Amsterdam JD, Berwish N (1987) Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy. J Clin Psychopharmacol 7: 238–242

    Article  CAS  PubMed  Google Scholar 

  • Aronson R, Offman HJ, Joffe RT et al. (1996) Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 53: 842–848

    Article  CAS  PubMed  Google Scholar 

  • Arroll B, Mac Gillivray S, Ogston S et al. (2005) Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3: 449–456

    Article  PubMed  PubMed Central  Google Scholar 

  • Artigas F, Romero L, de Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19: 378–383

    Article  CAS  PubMed  Google Scholar 

  • Bader G, Hawley JM, Short DD (1998) Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. J Clin Psychopharmacol 18: 255–256

    Article  CAS  PubMed  Google Scholar 

  • Ballenger JC (1988) The clinical use of carbamazepine in affective disorders. J Clin Psychiatry [Suppl] 49: 13–19

    PubMed  Google Scholar 

  • Barbee JG, Jamhour NJ (2002) Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 63 (Suppl 8): 737–741

    Article  CAS  PubMed  Google Scholar 

  • Barbee JG, Conrad EJ, Jamhour NJ (2004) The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 65: 975–981

    Article  CAS  PubMed  Google Scholar 

  • Barbosa L, Berk M, Vorster M (2003) A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 64: 403–407

    Article  CAS  PubMed  Google Scholar 

  • Baron BM, Ogden A, Seigel BW et al. (1988) Rapid down regulation of ß-adrenoreceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 154: 125–134

    Article  CAS  PubMed  Google Scholar 

  • Bauer M, Linden M (1993) Die Kombination verschiedener Antidepressiva in der Behandlung therapieresistenter Depressionen. Nervenarzt 64: 343–347

    CAS  PubMed  Google Scholar 

  • Bauer M, Hellweg R, Gräf KJ, Baumgartner A (1998) Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 18: 444–445

    Article  CAS  PubMed  Google Scholar 

  • Bauer M, Döpfmer S (1999) Lithium augmentation in treatment-resistant depression – a meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19: 427–434

    Article  CAS  PubMed  Google Scholar 

  • Bauer M, Whybrow PC (2001) Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2: 57–67

    Article  Google Scholar 

  • Bauer M, Forsthoff A, Baethge C et al. (2003) Lithium augmentation therapy in refractory depression – update 2002. Eur Arch Psychiatry Clin Neurosci 253: 132–139

    Article  PubMed  Google Scholar 

  • Bauer M, Pretorius HW, Constant EL et al. (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70: 540–549

    Article  CAS  PubMed  Google Scholar 

  • Baumgartner A (1993) Schilddrüsenhormone und depressive Erkrankungen. Teil I Nervenarzt 64: 1–10

    CAS  Google Scholar 

  • Beaumont G (1973) Drug interactions with clomipramine (Anafranil). J Int Med Res 1: 480–484

    Article  Google Scholar 

  • Bech P, Fava M, Trivedi MH et al. (2012) Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 125: 342–348

    Article  CAS  PubMed  Google Scholar 

  • Berlanga C, Ortega-Soto HA (1995) A 3-year follow-up of a group of treatment resistant depressed patients with a MAO/tricyclic combination. J Affect Disord 34: 197–1982

    Article  Google Scholar 

  • Berman RM, Marcus RN, Swanink R et al. (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 843–853

    Article  CAS  PubMed  Google Scholar 

  • Berman RM, Fava M, Thase ME et al. (2009) Aripiprazole augmentation in major depresive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS spectr 14: 937–948

    Google Scholar 

  • Blier P, Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15: 217–222

    Article  CAS  PubMed  Google Scholar 

  • Blier P (2006) Medication combination and augmentation strategies in the treatment of major depression, in: The American Psychiatric Publishing Textbook of Mood Disorders. In: Stein DJ, Kupfer DJ, Schatzberg AF (eds) Washington, DC, American Psychiatric Publishing, pp 509–524

    Google Scholar 

  • Blier P, Gobbi G, Turcotte JE et al. (2009) Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination. Eur Neuropsychopharmacol 19: 457–465

    Article  CAS  PubMed  Google Scholar 

  • Blier P, Ward HE, Tremblayx P et al. (2010) Combination of antidepressant medications form treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167: 281–288

    Article  PubMed  Google Scholar 

  • Bobo WV, Chen H, Trivedi MH et al. (2011) Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. J Affect Disord 133: 467–476

    Article  CAS  PubMed  Google Scholar 

  • Bodkin JA, Lasser RA, Wines JDJ et al. (1997) Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 58: 137–145

    Article  CAS  PubMed  Google Scholar 

  • Bonnet U (2003) Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 9: 97–140

    Article  CAS  PubMed  Google Scholar 

  • Boukoms A, Mangini L (1993) Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull 29: 207–211

    Google Scholar 

  • Boyer EW, Shannon M (2005) The serotonin syndrome. N Engl J Med 352: 1112–1120

    Article  CAS  PubMed  Google Scholar 

  • Boyer WF, Feighner JP (1993) The combined use of fluoxetine and bupropion (abstract). 146th Annual Meeting of the American Psychiatric Association, San Francisco

    Google Scholar 

  • Bressa GM (1994) S-adenosyl-L-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 154: 7–14

    Article  CAS  PubMed  Google Scholar 

  • Bschor T, Canata B, Müller-Oerlinghausen B et al. (2001) Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disorders 64: 261–265

    Article  CAS  PubMed  Google Scholar 

  • Bschor T, Berghöfer A, Ströhle A et al. (2002) How long should the lithium augmentation strategy be maintained A 1-year-follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 22: 427–430

    Article  CAS  PubMed  Google Scholar 

  • Bschor T, Lewitzka U, Sasse J et al. (2003) Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry 36 (Suppl 3): 230–234

    Google Scholar 

  • Bschor T, Lewitzka U, Pfennig A et al. (2007) Fünfundzwanzig Jahre Lithiumaugmentation. Nervenarzt 78: 1237–1247

    Article  CAS  PubMed  Google Scholar 

  • Caglieri-Cingolani R, Bencini A (1982) Due case mortali di reazione tossica per assoziazione di farmace antidepressivi inhibitori delle monoamino-ossidase e tricyclici. Riv Pat Nerv Ment 103: 21–31

    Google Scholar 

  • Calabrese JR, Suppes T, Sachs GS (1999) A double blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 60: 79–88

    Article  CAS  PubMed  Google Scholar 

  • Canadian Psychiatric Association (2001) Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry [Suppl] 46 (Suppl 1): 5–90

    Google Scholar 

  • Carpenter LL, Jocic Z, Hall JM et al. (1999) Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 60: 45–49

    Article  CAS  PubMed  Google Scholar 

  • Carpenter LL, Yasmin S, Price H (2002) A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51: 183–188

    Article  CAS  PubMed  Google Scholar 

  • Cassano P, Lattanzi L, Fava M et al. (2005) Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 50: 357–360

    Article  PubMed  Google Scholar 

  • Charney DS, Price LH, Heninger GR (1986) Desipramine-Yohimbine combination treatment for refractory depression. Arch Gen Psychiatry 43: 1155–1161

    Article  CAS  PubMed  Google Scholar 

  • Chiarello RJ, Cole JO (1987) The use of psychostimulants in general psychiatry. Arch Gen Psychiatry 44: 286–295

    Article  CAS  PubMed  Google Scholar 

  • Clayton AH, McGarvey EL, Abouesh AI et al. (2001) Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J Clin Psychiatry 62: 185–190

    Article  CAS  PubMed  Google Scholar 

  • Cohen SN, Armstrong MF (1974) Drug interactions: a handbook for clinical use. Williams & Wilkins, Baltimore

    Google Scholar 

  • Connolly KR, Thase ME (2011) If a first you don’t succeed. Drugs 7: 43–46

    Article  Google Scholar 

  • Coppen A, Bailey J (2000) Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 60: 121–130

    Article  CAS  PubMed  Google Scholar 

  • Corya SA, Williamson D, Sanger TM et al. (2006) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depression and Anxiety 23: 364–372

    Article  CAS  PubMed  Google Scholar 

  • Coryell W (2000) Augmentation strategies for inadequate antidepressant response: a review of placebo-controlled studies. Ann Clin Psychiatry 12: 141–146

    Article  CAS  PubMed  Google Scholar 

  • Coryell W (2011) The search for improved antidepressant strategies: is bigger better? nAm J Psychiatry 168: 664–666

    Google Scholar 

  • Crossley NA, Bauer M (2007) Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 68: 935–940

    Article  CAS  PubMed  Google Scholar 

  • Cusin C, Iovieno N, Iosifescu DV et al. (2013) A randomized, double-blind, placebo-controlled trial of pramipexole augmenawtion in treatment-resistant major depressive disorder. J Clin Psychiatry 74: 636–641

    Article  CAS  Google Scholar 

  • Dam J, Ryde L, Svejso J, Lauge N et al. (1998) Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 31: 48–54

    Article  CAS  PubMed  Google Scholar 

  • Dams R, Benijts TH, Lambert WE et al. (2001) A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol 25: 147–151

    Article  CAS  PubMed  Google Scholar 

  • Davidson J (1982) Adding a tricyclic antidepressant to a monoamine oxidase inhibitor. J Clin Psychopharmacol 3: 216

    Article  Google Scholar 

  • Davidson J, Mc Leod MN, Law-Yone B, Linnoila M (1978) A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry 35: 639–642

    Article  CAS  PubMed  Google Scholar 

  • Davis LL, Kabel D, Patel D, Choate AD et al. (1996) Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 32: 647–652

    CAS  PubMed  Google Scholar 

  • Dawson LA, Nguyen HQ (2000) The role of 5-HAT(1A) and 5-HAT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HAT: the mechanism of action of (+/-) pindolol. Neuropharmacology 39: 1044–1052

    Article  CAS  PubMed  Google Scholar 

  • DeBattista C (2006) Augmentation and combination strategies for depression. J Psychopharmacol 20: 11–18

    Article  CAS  PubMed  Google Scholar 

  • DeBattista C, Doghramji K, Menza M et al. (2003a) Adjunct modafinil for the shortterm treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 64: 1057–1064

    Article  CAS  PubMed  Google Scholar 

  • DeBattista C, Solvason HB, Poirier J et al. (2003b) A prosepctive trial of bupropion SR augmentation of partial and non-responsers to serotonergic antidepressants. J Clin Psychopharmacol 23: 27–30

    Article  CAS  PubMed  Google Scholar 

  • Debonnel G, Gobbi G, Turcotte J et al. (2000) The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology, Dec 10–14, San Juan, Puerto Rico

    Google Scholar 

  • De la Gandara J, , Rojo AL, , Ros S et al. (2005) Use of antidepressant combinations: which, when and why? results of a panish survey. Acta Psychiatr Scand 112 (Suppl 428): 32–36

    Google Scholar 

  • De Montigny C (1994) Lithium addition in treatment resistant depression. Int Clin Psychopharmacol 9 [Suppl] 2: 31–35

    Article  Google Scholar 

  • Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (2009) S3-Leitlinie unipolare Depresion. Darmstadt, Steinkopff

    Google Scholar 

  • Devarajan S, Dursun SM (2000) Citalopram plus reboxetine in treatment-resistant depression. Can J Psychiatry 45: 489–490

    Article  CAS  PubMed  Google Scholar 

  • Devarajan S, Dursun SM (2005) Olanzapine plus venlafaxine in treatment-resistant depression. J Psychopharmacol 19: 434–435

    Article  CAS  PubMed  Google Scholar 

  • Dietrich DE, Emrich HM (1998) The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 59 [Suppl] 5: 51–58

    Google Scholar 

  • Dimitriou EC, Dimitriou CE (1998) Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 18: 465–469

    Article  CAS  PubMed  Google Scholar 

  • Dodd S, Horgan D, Malhi G et al. (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89: 1–11

    Article  CAS  PubMed  Google Scholar 

  • Doree JP, Des Rosiers J, Gendron LV et al. (2007) Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 23: 333–341

    Article  CAS  PubMed  Google Scholar 

  • Dunner LD, Amsterdam JD, Shelton RC et al. (2003) Adjunctive ziprasidone in treatment-resistant depression: a pilot study. 156th Annual Meeting of the APA, May 17–22 2003, San Francisco, California, USA

    Google Scholar 

  • Ebert D, Albert R, May A et al. (1995) Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy. Psychopharmacology (Berl) 119: 342–344

    Article  CAS  Google Scholar 

  • El-Khalili N, Joyce M, Atkinson S et al. (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13: 917–932

    Article  CAS  PubMed  Google Scholar 

  • Erbe S, Gutwinski S, Bschor T (2012) Augmentation von Antidepressiva mit atypischen Antipsychotika bei Nonresponse auf eine Antidepressiva-Monotherapie. Psychiat Prax 39: 57–63

    Article  Google Scholar 

  • Erbe S, Pellert UN (2014) Folate in der Depressionsbehandlung. Fortschr Neurol Psychiatr 82: 78–83

    Article  CAS  PubMed  Google Scholar 

  • Erfurth A, Möller HJ (2000) Vorgehen bei Antidepressiva-Nonrespondern. In: Möller HJ (Hrsg) Therapie psychiatrischer Erkrankungen, 2. Aufl. Thieme, Stuttgart New York, S 407–412

    Google Scholar 

  • Farah A (1999) Relief of SSRI-induced sexual dysfunction with mirtazapine treatment (letter). J Clin Psychiatry 60: 260–261

    Article  CAS  PubMed  Google Scholar 

  • Fava M, Rush AJ (2006) Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 3: 139–153

    Article  Google Scholar 

  • Fava M (2001) Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 62 [Suppl] 18: 4–11

    Google Scholar 

  • Fava M, Rosenbaum JF, Mc Grath PJ, Stewart JW et al. (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double blind controlled study. Am J Psychiatry 151: 1372–1374

    Article  CAS  PubMed  Google Scholar 

  • Fava M, Alpert J, Nierenberg AA et al. (2002) Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 22: 379–387

    Article  CAS  PubMed  Google Scholar 

  • Fawcett J, Kravietz HM, Zajecka MR (1991) CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 11: 127–132

    Article  CAS  PubMed  Google Scholar 

  • Feighner JP, Herbstein J, Damlouji N (1985) Combination MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 46: 206–209

    CAS  PubMed  Google Scholar 

  • Feighner JP, Boyer WF, Tyler DL, Neborsky RJ (1990) Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 51: 222–225

    CAS  PubMed  Google Scholar 

  • Ferreri M, Lavergne F, Berlin I et al. (2001) Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 103: 66–72

    Article  Google Scholar 

  • Fleishaker JC (2000) Clinical pharmacokinetics of reboxetine, a selective nonrepinephirine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 39: 413–427

    Article  CAS  PubMed  Google Scholar 

  • Flockhart DA (2012) Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. J Clin Psychiatry 73, Suppl 1: 17–24

    Article  CAS  PubMed  Google Scholar 

  • Fredman SJ, Fava M, Kienke AS et al. (2000) Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. J Clin Psychiatry 61: 403–408

    Article  CAS  PubMed  Google Scholar 

  • Frye MA, Ketter TA, Leverich GS et al. (2000) The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61: 9–15

    Article  CAS  PubMed  Google Scholar 

  • Gander DR (1965) Treatment of depressive illnesses with combined antidepressants. Lancet I: 107–109

    Google Scholar 

  • Gerner RH, Kaufman KR, Rosen R (1998) Seizures associated with bupropion and SSRI cotherapy (abstract) Biol Psychiatry 43: 995

    Google Scholar 

  • Goforth HW, Carroll BT (2007) Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression. J Clin Psychopharmacol 27: 216–217

    Article  PubMed  Google Scholar 

  • Goldberg RS, Thornton WE (1978) Combined tricyclic-MAOI therapy for refractory depression: a review, with guidelines for appropriate usage. J Clin Pharmacol 18: 143–147

    Article  CAS  PubMed  Google Scholar 

  • Goodwin FK, Prange AJ, Post RM et al. (1982) A potentiation of antidepressant effect by l-triotdothyronine in tricyclic nonresponders. Am J Psychiatry 139: 34–38

    Article  CAS  PubMed  Google Scholar 

  • Gupta S, Ghaly N, Dewan M (1992) Augmenting fluoxetine with dextroamphetamine to treat refractory depression. Hosp Com Psychiat 43: 281–283

    CAS  Google Scholar 

  • Guscott R, Grof P (1991) The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 148: 695–704

    Article  CAS  PubMed  Google Scholar 

  • Härter M, Sitta P, Keller F, Metzger R, Wiegand W, Schell G et al. (2004) Stationäre psychiatrisch-psychotherapeutische Depressionsbehandlung. Prozess- und Ergebnisqualität anhand eines Modellprojekts in Baden-Württemberg. Nervenarzt 75: 1083–1091

    Article  PubMed  Google Scholar 

  • Harkin A, Kelly JP, McNamara M et al. (1999) Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 364: 123–132

    Article  CAS  PubMed  Google Scholar 

  • Hawley C, Sivakumaran T, Ochocki M, Bevand J (2000a) Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors in twenty-four patients with major depression (abstract). 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) Brussels

    Google Scholar 

  • Hawley CJ, Loughlin PJ, Quick SJ et al. (2000b) Efficacy, safety and tolerability of combined administration of lithium and selective serotonin reuptake inhibitors: a review of the current evidence. Int Clin Psychopharmacology 15: 197–206

    Article  CAS  Google Scholar 

  • Hawley CJ, Quick SJ, Ratnam S (1996) Safety and tolerability of combined treatment with moclobemide and SSRI: a systematic study of 50 patients. Int Clin Psychopharmacol 11: 187–191

    Article  CAS  PubMed  Google Scholar 

  • Hodgman MJ, Martin TG, Krenzelok EP (1997) Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Human Exp Toxicol 16: 14–17

    Article  CAS  Google Scholar 

  • Hüttemann K, Nowe T, Köhrmann M et al. (2009) Maligne Hyperthermie und deren Differentialdiagnsoen. Fortschr Neurol Psychiat 77: 203–211

    Article  PubMed  Google Scholar 

  • Inoue T, Tsuchiya K, Miura J et al. (1996) Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 40: 151–153

    Article  CAS  PubMed  Google Scholar 

  • Iosifescu DV, Nierenberg AA, Mischoulon D et al. (2005) An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry 66: 1038–1042

    Article  CAS  PubMed  Google Scholar 

  • Joffe RT, Roy-Byrne PP, Uhde TW, Post RM (1984) Thyroid function and affective illness: a reappraisal. Biol Psychiatry 19: 1685–1691

    CAS  PubMed  Google Scholar 

  • Joffe RT, Singer W, Levitt AJ, MacDonald C (1993a) A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 50: 387–393

    Article  CAS  PubMed  Google Scholar 

  • Joffe RT, Schuller DR (1993b) An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 54: 269–271

    CAS  PubMed  Google Scholar 

  • Joffe RT, Lewitt AJ, Bagby RM et al. (1993c) Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic nonresponders. Br J Psychiatry 163: 574–578

    Article  CAS  PubMed  Google Scholar 

  • Joffe RT, Bakish D (1994) Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 55: 24–25

    CAS  PubMed  Google Scholar 

  • Joffe RT, Sokolov ST (1994) Thyroid hormones, the brain, and affective disorders. Crit Rev Neurobiol 8: 45–63

    CAS  PubMed  Google Scholar 

  • Johnson GF (1987) Lithium in depression: a review of the antidepressant and prophylactic effects of lithium. Aust NZJ Psychiatry 21: 356–365

    Article  CAS  Google Scholar 

  • Khan A, Warner HA, Brown WA (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57: 311–317

    Article  CAS  PubMed  Google Scholar 

  • Keitner GI, Garlow SJ, Ryan CE et al. (2009) A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 43: 205–214

    Article  PubMed  Google Scholar 

  • Keltner N, Harris CP (1994) Serotonin syndrome: a case of fatal SSRI/MAOI interaction. Perspect Psychiatr Care 30: 26–31

    Article  CAS  PubMed  Google Scholar 

  • Kemp LI (1992) Sodium valproate as an antidepressant. Br J Psychiatry 160: 121–123

    Article  CAS  PubMed  Google Scholar 

  • Köhler S, Stöver L, Bschor T (2014) MAO-Hemmer als Behandlungsoption der therapieresistenten Depression: Anwendung, Wirksamkeit und Besonderheiten. Fortschr Neurol Psychiat 82 (im Druck)

    Google Scholar 

  • Köhler S, Unger T, Hoffmann S (2013) Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study. Pharmacopsychiatry 46: 69–76

    PubMed  Google Scholar 

  • Koenig F, Baumann P, Wolfersdorf M et al. (1997a) Hypertensive Reaktion nach Kombinationstherapie von Moclobemid, Trimipramin und Omeprazol. Nervenheilkunde 16: 55–59

    Google Scholar 

  • Koenig F, Wolfersdorf M (1997b) Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatry 30: 93–96

    Article  CAS  Google Scholar 

  • Konstantinidis A, Papageorgiou K, Grohmann R et al. (2012) Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmacol 15: 449–457

    Article  CAS  PubMed  Google Scholar 

  • Labbate LA, Grimes JB, Hines A et al. (1997) Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry 9: 241–245

    Article  CAS  PubMed  Google Scholar 

  • Lam RW, Wan DD, Cohen NL, Kennedy SH (2002) Combining antidepressants for treatment-resistant depression. A review. J Clin Psychiatry 63: 685–693

    Article  CAS  PubMed  Google Scholar 

  • Lam RW, Hossie H, Solomons K et al. (2004) Citalopram and bupropion SR: combining vs. switching in patients with treatment-resistant depression. J Clin Psychiatry 65: 337–340

    Article  CAS  PubMed  Google Scholar 

  • Landen M, Bjorling G, Agren H et al. (1998) A randomized, double-blind, placebocontrolled trial of buspirone in combination with an SSRI in patients with treatment refractory depression. J Clin Psychiatry 59: 664–668

    Article  CAS  PubMed  Google Scholar 

  • Lattanzi L, Cassano P, Dell’Osso L et al. (2000) Adjunctive pramipexole in treatment resistant depression. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology, Dec 10–14 San Juan, Puerto Rico

    Google Scholar 

  • Lejoyeux M, Adès J, Rouillon F (1994) Serotonin syndrome. Incidence, symptoms and treatment. CNS Drugs 2: 132–143

    Article  Google Scholar 

  • Licht RW, Qvitzau S (2002) Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 161: 143–151

    Article  CAS  Google Scholar 

  • Linet LS (1989) Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine (letter). Am J Psychiatry 146: 803–804

    CAS  PubMed  Google Scholar 

  • Loveless AH, Maxwell DR (1965) A comparison of the effects of imipramine, trimipramine, and some other drugs in rabbits treated with a monoamine oxidase inhibitor. Br J Pharmacol 25: 158–170

    CAS  Google Scholar 

  • Lucca A, Serretti A, Smeraldi E (2000) Effect of reboxetine augmentation in SSRI resistant patients. Hum Psychopharmacol 15: 143–145

    Article  CAS  PubMed  Google Scholar 

  • Maes M, Vandoolaeghe E, Desnyder R (1996) Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 41: 201–210

    Article  CAS  PubMed  Google Scholar 

  • Mahmoud RA, Pandina GJ, Turkoz I et al. (2007) Risperidone for treatment-refractory major depressive disorder. a randomized trial. Ann Intern Med 147: 593–602

    Article  PubMed  Google Scholar 

  • Marangell LB, Johnson CR, Kertz B et al. (2002) Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. J Clin Psychiatry 63: 391–395

    Article  CAS  PubMed  Google Scholar 

  • Marcus RN, McQuade RD, Carson WH et al. (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder. J Clin Psychopharmacol 28: 156–165

    Article  CAS  PubMed  Google Scholar 

  • Markovitz P, Wagner S (2003) An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 23: 1–3

    Article  Google Scholar 

  • Marks J (1965) Interaction involving drugs used in psychiatry. In: Marks J, Pare CMB (eds) The scientific basis of drug therapy in psychiatry. Pergamon, Oxford, pp 191–201

    Chapter  Google Scholar 

  • Marley E, Wozniak KM (1983) Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine reuptake inhibitors. Psychol Med 13: 735–749

    Article  CAS  PubMed  Google Scholar 

  • Marshall RD, Randall D, Johannet CM et al. (1995) Bupropion and sertraline combination treatment in refractory depression. J Psychopharmacol 9: 284–286

    Article  CAS  PubMed  Google Scholar 

  • Marshall RD, Liebowitz MR (1996) Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol 16: 80–81

    Article  CAS  PubMed  Google Scholar 

  • Mc Clellan KJ Spencer CM (1998) Modafinil – a review of its pharmacology and clinical efficacy in the management of narcolepsy. CNS Drugs 9: 311–324

    Article  CAS  Google Scholar 

  • McGrath PJ, Stewart JW, Fava M et al. (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a Star*D report. Am J Psychiatry 163: 1531–1541

    Article  PubMed  Google Scholar 

  • McIntyre RS, Muller A, Mancini DA et al. (2003) What to do if an initial antidepressant fails? Can Fam Physician 49: 449–457

    PubMed  PubMed Central  Google Scholar 

  • Menza MA, Kaufman KR, Castellanos A (2000) Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 61: 378–381

    Article  CAS  PubMed  Google Scholar 

  • Michelson D, Bancroft J, Targum S et al. (2000) Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry 157: 239–243

    Article  CAS  PubMed  Google Scholar 

  • Miller KK, Perlis RH, Papakostas GI et al. (2009) Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr 14: 688–694

    Article  PubMed  PubMed Central  Google Scholar 

  • Möller HJ (1991) Therapieresistenz auf Antidepressiva: Risikofaktoren und Behandlungsmöglichkeiten. Nervenarzt 62: 658–669

    PubMed  Google Scholar 

  • Möller HJ (1994) Non-response to antidepressants: risk factors and therapeutic possibilities. In Clin Psychopharmacol 9 (Suppl) 2: 17–23

    Google Scholar 

  • Möller HJ (2004a) Therapieresistenz auf Antidepressiva. Nervenarzt 75: 499–517

    Article  PubMed  Google Scholar 

  • Möller HJ (2004b) Medikamentöse Therapiestrategien bei therapieresistenter unipolarer Depression. Psychopharmakotherapie 11: 34–41

    Google Scholar 

  • Möller HJ (2005) Therapieresistenz unipolarer depressiver Erkrankungen: Häufigkeit, Prädiktoren, Risikofaktoren. In: Bauer M, Berghöfer A, Adli M (Hrsg.): Akute und therapieresistente Depressionen, 2 Aufl., S. 21–37. Springer, Heidelberg

    Chapter  Google Scholar 

  • Möller HJ, Kissling W, Stoll KD, Wendt G (1989) Psychopharmakotherapie. Kohlhammer, Stuttgart

    Google Scholar 

  • Moreno FA, Gelenberg AJ, Bachar K et al. (1997) Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry 58: 437–439

    Article  CAS  PubMed  Google Scholar 

  • Morris DW, Budhwar, Husain M et al. (2012) Depression treatment in patients with general medical conditions: results from the CO-MED trial. Ann Fam Med 10: 23–33

    Google Scholar 

  • Murphy DL, Sunderland T, Cohen RM (1984) Monoamine oxidase-inhibiting antidepressants – a clinical update. Psychiatr Clin North Am 7: 549–562

    CAS  PubMed  Google Scholar 

  • Nelson JC (1998a) Augmentation strategies with serotonin-noradrenergic combinations. J Clin Psychiatry 59: 65–68

    CAS  PubMed  Google Scholar 

  • Nelson JC (1998b) Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry 59 [Suppl] 15: 35–41

    Google Scholar 

  • Nelson JC (2000) Augmentation strategies in depression. J Clin Psychiatry 61 (Suppl 2): 13–19

    PubMed  Google Scholar 

  • Nelson JC (2003) Managing treatment-resistant major depression. J Clin Psychiatry 64: 5–12

    Article  CAS  PubMed  Google Scholar 

  • Nelson JC (2010) S-Adenosyl methionine (SAMe) augmentation in major depressive disorder. Am J Psychiatry 167: 889–891

    Article  PubMed  Google Scholar 

  • Nelson JC, Mazure CM, Bowers MBJ et al. (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48: 303–307

    Article  CAS  PubMed  Google Scholar 

  • Nelson JC, Mazure CM, Jatlow PI et al. (2004) Combining norepinephrine and serotonin reuptake inhibiton mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 55: 296–300

    Article  CAS  PubMed  Google Scholar 

  • Nelson JC, Pikalov A, Berman RM (2008) Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatric Dis Treatment 4: 937–948

    CAS  Google Scholar 

  • Nelson JC, Papakostas GI (2009a) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166: 980–991

    Article  PubMed  Google Scholar 

  • Nelson JC, Thase ME, Trivedi MH et al. (2009b) Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138–139 and CN 138–163). J Clin Psychiatry 11: 344–352

    Google Scholar 

  • Nelson JC, Mankoski R, Baker RA et al. (2010) Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptomsw of depression. a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disorders 120: 133–140

    Article  CAS  PubMed  Google Scholar 

  • Nemeroff CB (1996) Augementation strategies in patients with refractory depression. Depress Anxiety 4: 169–181

    Article  PubMed  Google Scholar 

  • Neuvonen P, Pohjola-Sintonen S, Tacke U et al. (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 342: 1419

    Article  CAS  PubMed  Google Scholar 

  • Nierenberg AA, Papakostas GI, Petersen T et al. (2003) Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 23: 92–95

    Article  CAS  PubMed  Google Scholar 

  • Nierenberg AA, Fava M, Trivedi MH (2006) A comparison of lithium and T3 augmentation following two failed medication treatments for depression: A Star*D report. Am J Psychiatry 163: 1519–1530

    Article  PubMed  Google Scholar 

  • Ninan PT, Hassman HA, Glass SJ, McManus FC (2004) Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry 65: 414–420

    Article  CAS  PubMed  Google Scholar 

  • Norman C, Hummel B, Schärer LO (2002) Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 63: 337–344

    Article  Google Scholar 

  • O'Brien S, McKeon P, O'Regan M (1993) The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. Br J Psychiatry 163: 363–368

    Article  Google Scholar 

  • Oefele v. K, Grohmann R, Hippius H, Rüther E (1988) Unerwünschte Arzneimittelwirkungen bei der Kombinationsbehandlung mit trizyklischen Antidepressiva und Monoaminoxidase-Hemmern. Nervenarzt 59: 118–123

    PubMed  Google Scholar 

  • Olver JS, Cryan JF, Burrows GD et al. (2000) Pindolol augmentation of antidepressants: a review and rationale. Aust N Z J Psychiatry 34: 71–79

    Article  CAS  PubMed  Google Scholar 

  • Ostroff RB, Nelson JC (1999) Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 60: 256–259

    Article  CAS  PubMed  Google Scholar 

  • Pande AC, Calarco MM, Grunhaus LJ (1991) Combined MAOI-TCA treatment in refractory depression. In: Amsterdam JD (ed) Advances in neuropsychiatry and psychopharmacology, vol 2: refractory depression. Raven Press, New York, pp 115–121

    Google Scholar 

  • Papakostas GI (2009) Evidence for S-Adenosyl-L-Methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry 70: 18–22

    Article  CAS  PubMed  Google Scholar 

  • Papakostas GI (2010) Switching, combination, and augmentation strategies for major depressive disorder. Ann Clin Psychiatry 22: 9–14

    Google Scholar 

  • Papakostas GI, Alpert JE, Fava M (2003) SAMe in the treatment of depression: a comprehensive review of the literature. Curr Psychiatry Rep 5: 460–466

    Article  PubMed  Google Scholar 

  • Papakostas GI, Petersen TJ, Nierenberg AA et al. (2004) Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant depressive disorder. J Clin Psychiatry 65: 217–221

    Article  CAS  PubMed  Google Scholar 

  • Papakostas GI, Petersen TJ, Kinrys G et al. (2005) Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 66: 1326–1330

    Article  CAS  PubMed  Google Scholar 

  • Papakostas GI, Worthington JJ, Iosifescu DV et al. (2006) The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 3: 178–181

    Article  CAS  Google Scholar 

  • Papakostas GI, Shelton RC, Smith J et al. (2007) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68: 826–831

    Article  CAS  PubMed  Google Scholar 

  • Papakostas GI, Fava M, Thase ME (2008a) Treatment of SSRI-resistant depression: a meta-analysis comparing within versus across-class switches. Biol Psychiatry 63: 699–704

    Article  CAS  PubMed  Google Scholar 

  • Papakostas GI, Shelton RC (2008b) Use of atypical antipsychotics for treatment-resistant major depressive disorder. Curr Psychiatry Reports 10: 481–486

    Article  Google Scholar 

  • Papakostas GI, Mischoulon D, Shyu I et al. (2010) S-Adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponsers with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 167: 942–948

    Article  PubMed  Google Scholar 

  • Papakostas GI, Shelton RC, Zajecka JM (2012a) L-Methylfolate as adjunctive therapy for SSR-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 169: 1267–1274

    Article  PubMed  Google Scholar 

  • Papakostas GI, Cassiello CF, Iovieno N (2012b) Folates and S-Adenosylmethionine for major depressive disorder. Can J Psychiatry 57: 406–413

    PubMed  Google Scholar 

  • Pare CMB (1964) Toxicity of psychotropic drugs: side effects and toxic effects of antidepressants. Proc R Soc Med 57: 757–778

    CAS  PubMed  PubMed Central  Google Scholar 

  • Pare CMB (1985) The present status of monoamine oxidase inhibitors. Br J Psychiatry 146: 576–584

    Article  CAS  PubMed  Google Scholar 

  • Perez V, Soler J, Puigdemont D et al. (1999) A double-blind, randomized, placebo controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 56: 375–379

    Article  CAS  PubMed  Google Scholar 

  • Perlis RH, Iosifescu DV, Alpert J et al. (2004) Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics 45: 224–229

    Article  CAS  PubMed  Google Scholar 

  • Petty F, Trivedi MH, Fulton M, Rush AJ (1995) Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 38: 578–591

    Article  CAS  PubMed  Google Scholar 

  • Preskorn SH. (1996) Clinical pharmacology of selective serotonin re-uptake inhibitors. Caddo: Professional Communications

    Google Scholar 

  • Rapaport MH, Gharabawi GM, Canuso CM et al. (2006) Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31: 2505–2513

    Article  CAS  PubMed  Google Scholar 

  • Razzani J, White K, White J, Simpson G et al. (1983) The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. Arch Gen Psychiatry 40: 657–661

    Article  Google Scholar 

  • Reeves H, Batra S, May RS et al. (2008) Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 69: 1228–1236

    Article  CAS  PubMed  Google Scholar 

  • Resler G, Lavie R, Campos J et al. (2008) Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes. Neuroimmunomodulation 15: 145–152

    Article  CAS  PubMed  Google Scholar 

  • Rickels K, Amsterdam JD, Clary C et al. (1991) Buspirone in major depression: a controlled study. J Clin Psychiatry 52: 34–38

    CAS  PubMed  Google Scholar 

  • Robertson P Jr, Hellriegel ET (2003) Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 42: 123–137

    Article  CAS  PubMed  Google Scholar 

  • Rocha FL, Hara C (2003) Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol 18: 97–99

    Article  PubMed  Google Scholar 

  • Ros S, Agüera L, de la Gandara J et al. (2005) Potentiation strategies for treatment-resistant depression. Acta Psychiatr Scand 112 (Suppl 428): 14–24

    Article  Google Scholar 

  • Rosenthal JS, Kaswan MJ, Hemlock C, Winston A (1991) Fluoxetine enhancement of heterocyclic antidepressants. In: Amsterdam JD (ed) Advances in neuropsychiatry and psychopharmacology, vol 2: refractory depression. Raven Press, New York, pp 105–108

    Google Scholar 

  • Rothschild BS (1994) Fluoxetine-nortriptyline therapy of treatment resistant major depression in a geriatric patient. J Geriatric Psych Neurol 7: 137–138

    Article  CAS  Google Scholar 

  • Rubio G, San L, Lopez-Munoz F et al. (2004) Reboxetine adjunct for partial or nonresponsers to antidepressant treatment. J Affect Disord 81: 67–72

    Article  CAS  PubMed  Google Scholar 

  • Rush AJ, Trivedi MH, Stewart JW (2011) Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168: 689–701

    Article  PubMed  Google Scholar 

  • Sachs G, Collins MA, Altshuler L et al. (2002) Divalproax sodium versus placebo for the treatment of bipolar depression. APA 2002, Syllabus & Proceedings Summary

    Google Scholar 

  • Schmauß M (1983) Miscellaneous new developments. In: Hippius H, Winokur G (eds) Psychopharmacology 1, part 2, Clinical psychopharmacology Excerpta Medica. Amsterdam, Oxford, Princeton, pp 178–185

    Google Scholar 

  • Schmauß M (2002) Kombinationstherapie nicht-selektiver Monoamin-Rückaufnahme-Inhibitoren mit MAO-Hemmern. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd 3: Antidepressiva Phasenprophylaktika und Stimmungsstabilisierer, 2. Aufl. Springer, Wien New York, S 551–557

    Google Scholar 

  • Schmauß M, Kapfhammer HP, Meyr P, Hoff P (1988a) Combined MAO-inhibitor and tri(tetra)cyclic antidepressant treatment in therapy resistant depression. Prog Neuro Psychopharmacol Biol Psychiatry 12: 523–532

    Article  Google Scholar 

  • Schmauß M, Laakmann G, Dieterle D (1988b) Effects of alpha-receptor blockade in addition to tricyclic antidepressants in therapy resistant depression. J Clin Psychopharmacol 8: 108–111

    Article  PubMed  Google Scholar 

  • Schmauß M, Erfurth A (1996) Kombinationstherapien bei Therapieresistenz auf Antidepressiva. Fortschr Neurol Psychiat 64: 390–402

    Article  PubMed  Google Scholar 

  • Schmauß M, Messer T (2009) Kombination von Antidepressiva – eine sinnvolle Behandlungsstrategie bei therapieresistenten Depressionen? Fortschr Neurol Psychiat 77: 316–325

    Article  PubMed  Google Scholar 

  • Schöpf J (1989) Lithiumzugabe zu Thymoleptika als Behandlung therapieresistenter Depressionen. Nervenarzt 60: 200–205

    PubMed  Google Scholar 

  • Schuckit M, Robins E, Feighner J (1971) Tricyclic antidepressants and monoamine oxidase inhibitors. Arch Gen Psychiatry 24: 509–514

    Article  CAS  PubMed  Google Scholar 

  • Schüle C, Baghai TC, Eser D et al. (2007) Mirtazapine monotherapy versus combination therapiy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J Biol Psychiatry 8: 112–122

    Article  PubMed  Google Scholar 

  • Seth R, Jennings AL, Bindman J, Phillips J et al. (1992) Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 161: 562–565

    Article  CAS  PubMed  Google Scholar 

  • Sethna ER (1974) A study of refractory cases of depressive illness and their response to combined antidepressant treatment. Br J Psychiatry 124: 265–272

    Article  CAS  PubMed  Google Scholar 

  • Shapira B, Oppenheim G, Zoher J, Segal M et al. (1985) Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biol Psychiatry 20: 576–579

    Article  CAS  PubMed  Google Scholar 

  • Shelton RC, Tollefson GD, Tohen M, Stahl S et al. (2001) A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158: 131–134

    Article  CAS  PubMed  Google Scholar 

  • Shelton RC, Williamson DJ, Corya SA et al. (2005) Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 66: 1289–1297

    Article  CAS  PubMed  Google Scholar 

  • Shelton RC, Papakostas GI (2008) Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 117: 253–259

    Article  CAS  PubMed  Google Scholar 

  • Sherwin BB (1991) Estrogen and refractory depression. In: Amsteram JD (ed) Advances in neuropsychiatry and psychopharmacology, vol 2: refractory depression. Raven Press, New York, pp 209–218

    Google Scholar 

  • Sjöqvist F (1965) Psychotropic drugs II: interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med 58: 967–978

    PubMed  PubMed Central  Google Scholar 

  • Souery D, Amsterdam J, de Montigny C et al. (1999) Treatment resistant depression: methodological overview and operational criteria: Eur Neuropsychopharmacol 9: 83–91

    Article  CAS  PubMed  Google Scholar 

  • Souery D, Papakostas GI, Trivedi MH (2006) Treatment-resistant depression. J Clin Psychiatry 67 (Suppl 6): 16–22

    PubMed  Google Scholar 

  • Spier SA (1998) Use of bupropion with SSRIs and venlafaxine. Depress Anxiety 7: 73–75

    Article  CAS  PubMed  Google Scholar 

  • Spiker DG, Pugh DD (1976) Combining tricyclic and monoamine oxidase inhibitor antidepressants. Arch Gen Psychiatry 33: 828–830

    Article  CAS  PubMed  Google Scholar 

  • Spillmann M, Fava M (1996) S-adenosylmethionine (Ademetionine) in psychiatric disorders: historical perspective and current status. CNS Drugs 6: 416–425

    Article  CAS  Google Scholar 

  • Sporn J, Ghaemi SN, Sambur MR et al. (2000) Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 12: 137–140

    Article  CAS  PubMed  Google Scholar 

  • Stahl SM, Felker A (2008) Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 13: 855–870

    Article  PubMed  Google Scholar 

  • Stein D, Avni J (1988) Thyroid hormones in the treatment of affective disorders. Acta Psychiatr Scand 77: 623–636

    Article  CAS  PubMed  Google Scholar 

  • Stein G, Bernadt M (1993) Lithium augmentation therapy in tricyclic resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 162: 634–640

    Article  CAS  PubMed  Google Scholar 

  • Sternbach H (1988) Danger of MAOI therapy after fluoxetine withdrawal. Lancet II: 850–851

    Google Scholar 

  • Stoll AL, Pillay SS, Diamond L et al. (1996) Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Pychiatry 57: 72–76

    CAS  Google Scholar 

  • Storosum JG, Elferink AJ, van Zwieten BJ et al. (2001) Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 11:173–180

    Article  CAS  PubMed  Google Scholar 

  • Takahashi H, Kamata M, Yoshida K (2008) Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series. Hum Psychopharmacol Clin Exp 23: 217–220

    Article  CAS  Google Scholar 

  • Targum SD, Greenberg RD, Harmon RL, Kessler K et al. (1984) Thyroid hormone and the TRH stimulation test in refractory depression. J Clin Psychiatry 45: 345–346

    CAS  PubMed  Google Scholar 

  • Thase ME (2011) Antidepressant combinations: widely used, but far from empirically validated. Can J Psychiatry 56: 317–323

    Article  PubMed  Google Scholar 

  • Thase ME, Trivedi MH, Nelson JC et al. (2008) Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. J Clin Psychiatry 10: 440–447

    Google Scholar 

  • Trivedi MH (2003) Treatment-resistant depression: new therapies on the horizont. Ann Clin Psychiatry 15: 59–70

    Article  PubMed  Google Scholar 

  • Trivedi MH, Kleiber BA (2001) Using treatment algorithms for the effective management of treatment-resistant depression. J Clin Psychiatry 62 [Suppl 6] 18: 22–29

    Google Scholar 

  • Trivedi MH, Fava M, Wisniewski SR et al. (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 12: 1243–1252

    Article  Google Scholar 

  • Vaughan DA (1988) Interaction of fluoxetin with tricyclic antidepressants (letter). Am J Psychiatry 145: 1478

    CAS  PubMed  Google Scholar 

  • Volz HP, Gleiter CH, Möller HJ (1996) Monoaminoxidasehemmer in der Psychiatrie. Nervenarzt 67: 339–347

    CAS  PubMed  Google Scholar 

  • Warneke L (1990) Psychostimulants in psychiatry. Can J Psychiatry 35: 3–10

    Article  CAS  PubMed  Google Scholar 

  • Warner MD, Peabody CA, Whiteford HA, Hollister LE (1988) Alprazolam as an antidepressant. J Clin Psychiatry 49: 148–150

    CAS  PubMed  Google Scholar 

  • Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS et al. (1989) Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 50: 447–449

    CAS  PubMed  Google Scholar 

  • Weilburg JB, Rosenbaum JF, Biedermann J et al. (1991) Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry 3: 209–213

    Article  Google Scholar 

  • White K, Pistole TA, Boyd J (1980) Combined monoamine oxidase inhibitor tricyclic antidepressant treatment. A pilot study. Am J Psychiatry 137: 1422–1425

    Article  CAS  PubMed  Google Scholar 

  • White K, Simpson G (1981) Combined MAOI-tricyclic antidepressant treatment. A reevaluation. J Clin Psychopharmacol 1: 264–282

    Article  CAS  PubMed  Google Scholar 

  • Whybrow PC, Prange AJ Jr (1981) A hypothesis of thyroid-catecholamine receptor interaction. Arch Gen Psychiatry 38: 106–113

    Article  CAS  PubMed  Google Scholar 

  • Winston F (1971) Combined antidepressant therapy. Br J Psychiatry 118: 301–304

    Article  CAS  PubMed  Google Scholar 

  • Young JPR, Lader MH, Hughes WC (1979) Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 2: 1315–1317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Young SJ (1996) Panic associated with combining fluoxetine and bupropion (letter). J Clin Psychiatry 57: 177–178

    CAS  PubMed  Google Scholar 

  • Zajecka JM, Jeffriess H, Fawcett J (1995) The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry 56: 338–343

    CAS  PubMed  Google Scholar 

  • Zisook S, Rush AJ, Haight BR et al. (2006) Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 59: 203–210

    Article  CAS  PubMed  Google Scholar 

  • Zullino D, Baumann P (2001) Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 34: 119–127

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bezirkskrankenhaus Augsburg, Bezirkskliniken Schwaben, Dr. Mack Straße 1, 86156, Augsburg, Deutschland

    Prof. Dr. Max Schmauß

  2. Danuviusklinik GmbH, Krankenhausstraße 68, 85276, Pfaffenhofen, Deutschland

    PD Dr. Thomas Messer

Authors
  1. Prof. Dr. Max Schmauß
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. PD Dr. Thomas Messer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Max Schmauß .

Editor information

Editors and Affiliations

  1. Danuvius Klinik Pfaffenhofen, Pfaffenhofen, Germany

    Thomas Messer

  2. und Psychosomatik, Bezirkskrankenhaus Augsburg Klinik für Psychiatrie, Psychotherapie,, Augsburg, Germany

    Max Schmauß

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Wien

About this chapter

Cite this chapter

Schmauß, M., Messer, T. (2016). Behandlung depressiver Störungen. In: Messer, T., Schmauß, M. (eds) Polypharmazie in der Behandlung psychischer Erkrankungen. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1849-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1849-8_1

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1848-1

  • Online ISBN: 978-3-7091-1849-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation